Core Insights - The BroncTarget lung-targeted denervation radiofrequency ablation system has entered the special review process of the National Medical Products Administration (NMPA) in China, indicating recognition of its core technology originality and clinical significance [1] - Targeted Lung Denervation (TLD) is a breakthrough intervention technique for moderate to severe Chronic Obstructive Pulmonary Disease (COPD), aiming to suppress airway abnormal contraction and mucus hypersecretion [1] - The BroncTarget system employs innovative designs such as circular multi-electrodes, adjustable orifices, differentiated output of radiofrequency energy, real-time monitoring of temperature and impedance, and intelligent saline infusion to ensure ablation efficiency and safety [1] Clinical Trials - Confirmatory clinical trials for the BroncTarget system are currently underway, with 28 hospitals across the country actively recruiting participants [2]